赛隆药业(002898) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥32,323,691.75, a decrease of 51.07% compared to ¥66,055,336.14 in the same period last year[7] - The net profit attributable to shareholders was a loss of ¥7,562,492.82, representing a decline of 340.28% from a profit of ¥3,147,316.23 in the previous year[7] - Basic and diluted earnings per share were both -¥0.047, a decrease of 347.37% from ¥0.019 in the previous year[7] - The company's operating revenue decreased by 51.07% to ¥32,323,691.75 compared to the previous period due to the impact of the pandemic[14] - The net profit for the current period is a loss of CNY 15,278,053.68, compared to a loss of CNY 8,010,112.60 in the previous period, representing an increase in loss of 90.5%[40] - The total comprehensive income for the current period is CNY -15,278,053.68, compared to CNY -8,010,112.60 in the previous period[41] Cash Flow and Liquidity - The net cash flow from operating activities improved to -¥7,059,640.39, a 78.41% increase compared to -¥32,700,765.89 in the same period last year[7] - The cash flow from operating activities shows a net outflow of CNY 7,059,640.39, an improvement from a net outflow of CNY 32,700,765.89 in the previous period[44] - The company’s cash and cash equivalents decreased to ¥92,538,391.31 from ¥96,265,749.64, indicating a decline in liquidity[26] - The cash and cash equivalents at the end of the period amount to CNY 92,538,391.31, down from CNY 153,012,117.23 at the end of the previous period[45] - The ending balance of cash and cash equivalents decreased to 26,206,794.30 yuan from 127,102,466.17 yuan, a decline of approximately 79.3%[48] Assets and Liabilities - Total assets at the end of the reporting period were ¥844,115,360.73, an increase of 0.97% from ¥835,978,330.13 at the end of the previous year[7] - The total assets of the company amounted to ¥844,115,360.73, showing a slight increase from ¥835,978,330.13 at the beginning of the period[26] - The company’s total liabilities increased to ¥192,653,528.91 from ¥176,954,005.49, reflecting a rise in financial obligations[28] - Total liabilities amounted to 176,954,005.49 yuan, with no changes reported in the equity section[51] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,401[10] - The largest shareholder, Cai Nanguai, holds 51.15% of the shares, amounting to 81,833,579 shares, with 12,700,000 shares pledged[10] Research and Development - Research and development expenses increased by 90.82% to ¥4,630,292.72, reflecting higher investment in R&D projects during the reporting period[14] - The company incurred research and development expenses of CNY 3,726,967.83, an increase of 32.3% from CNY 2,818,014.35 in the previous period[38] Government Support - The company received government subsidies amounting to ¥1,018,346.00 during the reporting period[8] - The company reported a significant increase in other income, which rose by 13,039.95% to ¥1,018,346.00, primarily due to government subsidies received[14] Operational Changes - The company did not engage in any repurchase transactions during the reporting period[11] - The company has adopted new revenue and leasing standards starting in 2020, impacting the presentation of pre-receivables[52] - The first quarter report for 2020 was not audited, indicating that the figures may be subject to adjustments[55]